LT3240801T - Kombinuota navikų imunoterapija - Google Patents
Kombinuota navikų imunoterapijaInfo
- Publication number
- LT3240801T LT3240801T LTEP15876030.6T LT15876030T LT3240801T LT 3240801 T LT3240801 T LT 3240801T LT 15876030 T LT15876030 T LT 15876030T LT 3240801 T LT3240801 T LT 3240801T
- Authority
- LT
- Lithuania
- Prior art keywords
- tumor immunotherapy
- combination tumor
- combination
- immunotherapy
- tumor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462098568P | 2014-12-31 | 2014-12-31 | |
| US201562106526P | 2015-01-22 | 2015-01-22 | |
| US201562118165P | 2015-02-19 | 2015-02-19 | |
| PCT/US2015/067269 WO2016109310A1 (en) | 2014-12-31 | 2015-12-22 | Combination tumor immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3240801T true LT3240801T (lt) | 2021-02-25 |
Family
ID=56284932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP15876030.6T LT3240801T (lt) | 2014-12-31 | 2015-12-22 | Kombinuota navikų imunoterapija |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10682365B2 (lt) |
| EP (2) | EP3835312A1 (lt) |
| JP (2) | JP6885867B2 (lt) |
| CN (2) | CN107428813B (lt) |
| AU (2) | AU2015374385B2 (lt) |
| CA (1) | CA2972757A1 (lt) |
| CY (1) | CY1123868T1 (lt) |
| DK (1) | DK3240801T3 (lt) |
| ES (1) | ES2856844T3 (lt) |
| HK (1) | HK1246319A1 (lt) |
| HR (1) | HRP20210200T1 (lt) |
| HU (1) | HUE053145T2 (lt) |
| LT (1) | LT3240801T (lt) |
| MX (2) | MX2017008658A (lt) |
| NZ (1) | NZ734144A (lt) |
| PL (1) | PL3240801T3 (lt) |
| PT (1) | PT3240801T (lt) |
| RS (1) | RS61470B1 (lt) |
| SI (1) | SI3240801T1 (lt) |
| WO (1) | WO2016109310A1 (lt) |
| ZA (1) | ZA202005298B (lt) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200030375A1 (en) * | 2012-06-27 | 2020-01-30 | Kenichiro Hasumi | Therapy and methods of introducing immature dendritic cells and/or cytoxic t lymphocyte and anti pd-1 / pd-l1 antibody for treatment of tumors |
| MX2015015037A (es) | 2013-05-02 | 2016-07-08 | Anaptysbio Inc | Anticuerpos dirigidos contra la proteina muerte programada-1 (pd-1). |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| AU2014361473B2 (en) | 2013-12-12 | 2019-09-26 | Jiangsu Hengrui Medicine Co., Ltd. | PD-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| CN107106493A (zh) | 2014-11-21 | 2017-08-29 | 西北大学 | 球形核酸纳米颗粒缀合物的序列特异性细胞摄取 |
| BR112017019559B1 (pt) | 2015-03-13 | 2020-08-04 | Cytomx Therapeutics, Inc | Anticorpos anti-pdl1, anticorpos anti-pdl1 ativáveis, e métodos de uso destes |
| JP6893608B2 (ja) | 2015-05-29 | 2021-06-23 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がんの処置のためのＰＤ−１アンタゴニストとＣｐＧ−Ｃ型オリゴヌクレオチドの併用 |
| MA42447A (fr) | 2015-07-13 | 2018-05-23 | Cytomx Therapeutics Inc | Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation |
| PT3682889T (pt) * | 2015-08-06 | 2023-03-09 | St Jude Childrens Res Hospital | Modulação de ativação de inflamassoma de células supressoras derivadas de mieloide para tratamento de gvdh |
| GB201516047D0 (en) | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
| EP3213768A1 (en) | 2016-03-01 | 2017-09-06 | LODOCO CLINICAL Kft | Combination of low dose immune checkpoint blockade with high dose il-2 for treating metastatic cancer |
| WO2017173334A1 (en) * | 2016-04-01 | 2017-10-05 | Checkmate Pharmaceuticals, Inc. | Fc receptor-mediated drug delivery |
| KR102590454B1 (ko) | 2016-07-07 | 2023-10-17 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| WO2018036852A1 (en) | 2016-08-25 | 2018-03-01 | F. Hoffmann-La Roche Ag | Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent |
| WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
| MX2019005117A (es) | 2016-11-01 | 2019-10-21 | Anaptysbio Inc | Anticuerpos dirigidos contra la muerte programada 1 (pd-1). |
| EP3558360A1 (en) | 2016-12-22 | 2019-10-30 | F. Hoffmann-La Roche AG | Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment |
| SG11201906192SA (en) | 2017-01-09 | 2019-08-27 | Tesaro Inc | Methods of treating cancer with anti-pd-1 antibodies |
| JP7082110B2 (ja) * | 2017-03-29 | 2022-06-07 | テルモ株式会社 | アジュバント組成物およびこれを含むワクチン組成物並びに薬剤キット |
| US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
| US11433131B2 (en) | 2017-05-11 | 2022-09-06 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (SNAs) |
| WO2018222949A1 (en) | 2017-06-01 | 2018-12-06 | Cytomx Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
| US20210030783A1 (en) * | 2018-02-13 | 2021-02-04 | Checkmate Pharmaceuticals, Inc. | Compositions and methods for tumor immunotherapy |
| KR20210006905A (ko) | 2018-04-09 | 2021-01-19 | 체크메이트 파마슈티칼스 | 바이러스-유사 입자 내로의 올리고뉴클레오타이드의 포장 |
| TW202011959A (zh) | 2018-04-14 | 2020-04-01 | 美商戴納瓦克斯技術公司 | 用於治療癌症之包括CpG-C 型寡核苷酸及組蛋白去乙醯酶抑制劑之組合 |
| CN108486120B (zh) * | 2018-04-28 | 2019-12-06 | 新乡医学院 | 一种新型CpG ODN序列及其在抗黑色素瘤上的应用 |
| EP3566718A1 (en) | 2018-05-07 | 2019-11-13 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | A pharmazeutical combination (treg depleting agent, checkpoint inhibitor, tlr9 agonist) for use in the treatment of cancer |
| JP7359785B2 (ja) * | 2018-06-05 | 2023-10-11 | 江蘇康寧杰瑞生物制薬有限公司 | 二量体及びその使用 |
| WO2020081398A1 (en) * | 2018-10-14 | 2020-04-23 | Dynavax Technologies Corporation | Combination including a cpg-c type oligonucleotide and a pd-1 antagonist for treating breast cancer |
| CN113226366A (zh) * | 2018-10-18 | 2021-08-06 | 艾德拉药物股份有限公司 | 用于治疗癌症的tlr9调节剂 |
| CN113993549A (zh) | 2019-03-15 | 2022-01-28 | 博尔特生物治疗药物有限公司 | 靶向her2的免疫缀合物 |
| TWI833056B (zh) * | 2019-12-31 | 2024-02-21 | 財團法人工業技術研究院 | 核酸藥物複合體以及其用途 |
| WO2022110010A1 (zh) * | 2020-11-27 | 2022-06-02 | 苏州吉玛基因股份有限公司 | 免疫激活剂、抗原和抗体在制备预防、治疗肿瘤产品中的应用 |
| CN114099535B (zh) * | 2020-12-10 | 2023-01-03 | 南京吉迈生物技术有限公司 | Toll样受体9(TLR9)激动剂水凝胶免疫调节组合物 |
| WO2023096934A1 (en) * | 2021-11-24 | 2023-06-01 | Wisconsin Alumni Research Foundation | Nanoparticles for potentiating effects of radiation therapy on anti-cancer immunotherapy |
| WO2023130072A1 (en) | 2022-01-03 | 2023-07-06 | Checkmate Pharmaceuticals, Inc. | Transcriptional biomarkers for response to innate immune activators |
| CN114982711B (zh) * | 2022-05-30 | 2023-11-10 | 广东省人民医院 | 小鼠胃间质瘤自发成瘤模型及其构建方法和应用 |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
| EP0092574B1 (en) | 1981-10-23 | 1992-04-29 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and methods of making same |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5177198A (en) | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE122007000078I2 (de) | 1991-06-27 | 2011-01-13 | Bristol Myers Squibb Co | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| PT1498427E (pt) | 1992-08-21 | 2010-03-22 | Univ Bruxelles | Imunoglobulinas desprovidas de cadeias leves |
| DE4321946A1 (de) | 1993-07-01 | 1995-01-12 | Hoechst Ag | Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung |
| US5859231A (en) | 1993-09-03 | 1999-01-12 | Duke University | Synthesis of oligonucleotides with boranophosphonate linkages |
| US5658738A (en) | 1994-05-31 | 1997-08-19 | Becton Dickinson And Company | Bi-directional oligonucleotides that bind thrombin |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| EP1167378B1 (en) | 1994-07-15 | 2011-05-11 | University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| US6160109A (en) | 1995-10-20 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Preparation of phosphorothioate and boranophosphate oligomers |
| US20020088014A1 (en) | 1996-05-31 | 2002-07-04 | Xiangming Fang | Minimal adenovirus mediated recombinant vaccine |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| DE19648625A1 (de) | 1996-11-13 | 1998-05-14 | Soft Gene Gmbh | Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer |
| US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| US20030207346A1 (en) | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
| JP2002506353A (ja) | 1997-06-24 | 2002-02-26 | ジェネンテック・インコーポレーテッド | ガラクトシル化糖タンパク質の方法及び組成物 |
| ATE419009T1 (de) | 1997-10-31 | 2009-01-15 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
| AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| DE19826758C1 (de) | 1998-06-15 | 1999-10-21 | Soft Gene Gmbh | Darstellung von linearen kovalent geschlossenen DNA-Molekülen als Expressionskonstrukte |
| WO2000006588A1 (en) | 1998-07-27 | 2000-02-10 | University Of Iowa Research Foundation | STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS |
| PT1123313E (pt) | 1998-10-23 | 2007-04-30 | Amgen Inc | Métodos e composições para a prevenção e tratamento da anemia |
| PT1137436E (pt) | 1998-12-03 | 2008-09-15 | Univ California | Estimulação das células t contra auto-antigénios por meio de agentes bloqueadores de ctla-4 |
| OA11917A (en) | 1998-12-23 | 2006-04-13 | Abgenix Inc | Human monoclonal antibodies to ctla-4. |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US6207819B1 (en) | 1999-02-12 | 2001-03-27 | Isis Pharmaceuticals, Inc. | Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds |
| DE19935756A1 (de) | 1999-07-27 | 2001-02-08 | Mologen Forschungs Entwicklung | Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation |
| WO2001014557A1 (en) | 1999-08-23 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| WO2001014424A2 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
| ES2306711T3 (es) | 2000-04-21 | 2008-11-16 | Amgen Inc. | Metodo y composicion destinada a la prevencion y al tratamiento de la anemia. |
| EP2009027B1 (en) | 2001-04-27 | 2014-05-21 | Kyowa Hakko Kirin Co., Ltd. | Anti-CD40 monoclonal antibody |
| IL149701A0 (en) | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| SI1446162T1 (sl) | 2001-08-17 | 2009-04-30 | Coley Pharm Gmbh | Kombinacija zaporedja imunostimulatornih oligonukleotidov z izboljšano aktivnostjo |
| CA2492826C (en) | 2001-09-14 | 2016-12-13 | Cytos Biotechnology Ag | Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use |
| WO2003031464A2 (en) | 2001-10-10 | 2003-04-17 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
| US7265084B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
| US7265085B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycoconjugation methods and proteins/peptides produced by the methods |
| US20030157108A1 (en) | 2001-10-25 | 2003-08-21 | Genentech, Inc. | Glycoprotein compositions |
| US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
| AU2003288675B2 (en) | 2002-12-23 | 2010-07-22 | Medimmune Limited | Antibodies against PD-1 and uses therefor |
| BRPI0408623A (pt) | 2003-03-26 | 2006-03-07 | Cytos Biotechnology Ag | conjugados de partìcula semelhante ao vìrus análogo de peptìdeo de melan-a |
| JP4945247B2 (ja) | 2003-12-30 | 2012-06-06 | モロゲン・アーゲー | 同種異系の腫瘍治療法 |
| WO2005080567A1 (de) | 2004-02-20 | 2005-09-01 | Mologen Ag | Substituiertes, nicht-kodierendes nukleinsäuremolekül zur therapeutischen und prophylaktischen immunstimulation in menschen und höheren tieren |
| MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| US20090117132A1 (en) | 2005-07-07 | 2009-05-07 | Pfizer, Inc. | Anti-Ctla-4 Antibody and Cpg-Motif-Containing Synthetic Oligodeoxynucleotide Combination Therapy for Cancer Treatment |
| WO2007059041A2 (en) * | 2005-11-11 | 2007-05-24 | Pfizer, Inc. | Combinations and methods of using an immunomodulatory oligodeoxynucleotide |
| JP5484732B2 (ja) | 2005-12-14 | 2014-05-07 | サイトス バイオテクノロジー アーゲー | 過敏症の治療のための免疫賦活性核酸パッケージ粒子 |
| DK2405002T3 (en) | 2006-02-15 | 2015-01-05 | Adiutide Pharmaceuticals Gmbh | Compositions and methods for oligonukleotidformuleringer |
| EP2019857B1 (en) | 2006-05-03 | 2016-09-28 | The Regents of the University of Colorado, a body corporate | Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity |
| ES2738986T3 (es) | 2006-06-12 | 2020-01-28 | Kuros Biosciences Ag | Procesos para empaquetar oligonucleótidos en partículas de tipo viral de bacteriófagos de ARN |
| PT2078080E (pt) | 2006-09-27 | 2015-09-18 | Coley Pharm Gmbh | Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada |
| WO2008073960A2 (en) | 2006-12-12 | 2008-06-19 | Integrated Dna Technologies, Inc. | Oligonucleotides containing high concentrations of guanine monomers |
| WO2009022215A1 (en) | 2007-08-13 | 2009-02-19 | Pfizer Inc. | Combination motif immune stimulatory oligonucleotides with improved activity |
| WO2012006634A2 (en) * | 2010-07-09 | 2012-01-12 | The Board Of Trustees Of The University Of Illiniois | Prostate specific antigen (psa) peptide therapy |
| AU2013255511B2 (en) * | 2012-05-04 | 2016-01-28 | Pfizer Inc. | Prostate-associated antigens and vaccine-based immunotherapy regimens |
| US9501570B2 (en) | 2014-07-14 | 2016-11-22 | Verizon Patent And Licensing Inc. | Dynamic routing system |
| US9719791B2 (en) | 2014-12-10 | 2017-08-01 | Mapquest, Inc. | Computerized systems and methods for providing travel information and/or content to users |
| JP6893608B2 (ja) * | 2015-05-29 | 2021-06-23 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がんの処置のためのＰＤ−１アンタゴニストとＣｐＧ−Ｃ型オリゴヌクレオチドの併用 |
| US9917100B2 (en) | 2015-11-20 | 2018-03-13 | Sandisk Technologies Llc | Three-dimensional NAND device containing support pedestal structures for a buried source line and method of making the same |
| ITUA20162720A1 (it) | 2016-04-19 | 2017-10-19 | Risco Spa | Apparecchiatura per preparare un prodotto alimentare |
-
2015
- 2015-12-22 DK DK15876030.6T patent/DK3240801T3/da active
- 2015-12-22 SI SI201531505T patent/SI3240801T1/sl unknown
- 2015-12-22 CN CN201580075681.0A patent/CN107428813B/zh active Active
- 2015-12-22 MX MX2017008658A patent/MX2017008658A/es unknown
- 2015-12-22 US US15/540,913 patent/US10682365B2/en active Active
- 2015-12-22 AU AU2015374385A patent/AU2015374385B2/en active Active
- 2015-12-22 PL PL15876030T patent/PL3240801T3/pl unknown
- 2015-12-22 JP JP2017535690A patent/JP6885867B2/ja active Active
- 2015-12-22 LT LTEP15876030.6T patent/LT3240801T/lt unknown
- 2015-12-22 EP EP21151085.4A patent/EP3835312A1/en active Pending
- 2015-12-22 CA CA2972757A patent/CA2972757A1/en active Pending
- 2015-12-22 ES ES15876030T patent/ES2856844T3/es active Active
- 2015-12-22 WO PCT/US2015/067269 patent/WO2016109310A1/en active Application Filing
- 2015-12-22 HU HUE15876030A patent/HUE053145T2/hu unknown
- 2015-12-22 RS RS20210195A patent/RS61470B1/sr unknown
- 2015-12-22 NZ NZ734144A patent/NZ734144A/en unknown
- 2015-12-22 CN CN202110797632.5A patent/CN113813386A/zh active Pending
- 2015-12-22 PT PT158760306T patent/PT3240801T/pt unknown
- 2015-12-22 EP EP15876030.6A patent/EP3240801B1/en active Active
-
2017
- 2017-06-28 MX MX2022008338A patent/MX2022008338A/es unknown
-
2018
- 2018-05-04 HK HK18105759.0A patent/HK1246319A1/zh unknown
-
2020
- 2020-05-05 US US16/867,296 patent/US20200281953A1/en active Pending
- 2020-08-20 ZA ZA2020/05298A patent/ZA202005298B/en unknown
- 2020-08-26 AU AU2020223671A patent/AU2020223671C1/en active Active
- 2020-11-10 JP JP2020187016A patent/JP2021014465A/ja not_active Withdrawn
-
2021
- 2021-02-04 HR HRP20210200TT patent/HRP20210200T1/hr unknown
- 2021-02-16 CY CY20211100130T patent/CY1123868T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202005298B (en) | Combination tumor immunotherapy | |
| IL304663A (en) | combination | |
| IL247073A0 (en) | combination | |
| GB201517022D0 (en) | No details | |
| GB201410907D0 (en) | No details | |
| GB201519531D0 (en) | No details | |
| GB201517404D0 (en) | No details | |
| PT3107573T (pt) | Imunoterapia com il-12 visada ao cancro | |
| GB201418217D0 (en) | No details | |
| GB201418216D0 (en) | No details | |
| HK1257177A1 (zh) | 腫瘤免疫治療 | |
| GB201517412D0 (en) | No details | |
| GB201517574D0 (en) | No details | |
| GB201516796D0 (en) | No details | |
| IL252086A0 (en) | New methods | |
| PL3094345T3 (pl) | Immunoterapia oparta na liposomach | |
| LT3237349T (lt) | Patobulintas biologinis rišiklis | |
| GB201517605D0 (en) | No details | |
| GB201508480D0 (en) | Cancer | |
| GB201410910D0 (en) | No details | |
| GB201414542D0 (en) | Novel therapy | |
| GB201801971D0 (en) | No details | |
| GB201604705D0 (en) | No details | |
| GB201604704D0 (en) | No details | |
| GB201604703D0 (en) | NO details |